Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The aim of the present study is to examine whether cerebral oxygenation could be a more useful parameter than peripheral oxygen saturation to guide clinical titration of permissive hypoxemia in COVID-19 ARDS patients
Description: Cardiovascular and pulmonary optimization: Step 0 = Baseline, Step 1 = Derecruitment, Step 2 = Recruitment, Step 3 = Norepinephrine challenge, Step 4 = FiO2 increase, Step 5 = FiO2 decrease, Step 6 = Baseline 2
Measure: Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in heart rate (HR) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in stroke volume (SV) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in cardiac output (CO) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in pH during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in PaO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in PaCO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in PvO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in PvCO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in lacatate during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization Time: 1 hourDescription: Cardiovascular and pulmonary optimization as described above
Measure: Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization Time: 1 hour